ArticleMolecular biology reports2025
Association of AGT and AGTR1 gene polymorphisms with chronic kidney disease: a case-control and in silico study.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic kidney disease (CKD) is a complex disease influenced by genetic and environmental factors. Polymorphisms in RAAS genes have been implicated in kidney disease, though their influence on disease susceptibility varies across studies. The AGT and AGTR1 are key candidate genes of the RAAS cascade, essential for kidney function. METHODS AND
resultsThis study investigated the association of AGT (rs699) and AGTR1 (rs5186) polymorphisms with susceptibility to CKD. A total of 380 participants were recruited in this hospital-based case-control study and genotyping was performed using PCR- RFLP method. Statistical analyses were conducted using SPSS Statistics version 26.0. Computational analysis was done to predict the pathogenicity of missense variant rs699 and its effect on structure and function of AGT; however, rs5186, a 3' UTR non-coding variant of the AGTR1 gene was excluded. Our findings showed that the AGT (rs699) T allele was more frequent in controls (46.9%) than in CKD cases (35.3%), suggesting a potential protective role against CKD (p = 0.001). No significant associations were observed in AGTR1 (rs5186) and CKD (p > 0.05). Furthermore, the studied polymorphisms did not significantly affect serum creatinine, urea, or eGFR levels in CKD patients. In silico analysis predicted the AGT rs699 variant to be likely benign, with slightly decreased AGT protein stability and binding affinity to renin.
conclusionsThe results suggest a significant association of the AGT (rs699) polymorphism with CKD. Computational findings support a limited functional impact of the rs699 variant. Further research, including functional studies and investigations in larger cohorts, is warranted to assess the potential of these polymorphisms as biomarkers for CKD risk.
Indexed as
Identifiers
41222805What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.